| AASLD

Home

MiR150 DEFICIENCY IN MACROPHAGES IMPROVES ALCOHOL INDUCED HEPATIC STEATOSIS VIA TRANSFERRING THYROID HORMONE RECEPTOR Β ENRICHED EVS TARGETING ADIPOSE TISSUE-LIVER AXIS: THYROID HORMONE RECEPTOR Β, A PROMISING THERAPEUTIC TARGET IN ALD

Read more about MiR150 DEFICIENCY IN MACROPHAGES IMPROVES ALCOHOL INDUCED HEPATIC STEATOSIS VIA TRANSFERRING THYROID HORMONE RECEPTOR Β ENRICHED EVS TARGETING ADIPOSE TISSUE-LIVER AXIS: THYROID HORMONE RECEPTOR Β, A PROMISING THERAPEUTIC TARGET IN ALD

<div>Background: The mechanisms of alcoholic hepatitis (AH) are complex and involve the cross talk between organ systems. MiR150, one of the most abundant microRNAs in immune cells, has been implicated in various liver diseases, but its role in AH pathogenesis remains unclear. We aimed to determine the role of the miR150-mediated immune cells-liver axis in AH pathogenesis.

HEPATOCYTE DELETION OF REGULATORY T CELLS BY ENCLYSIS IS INCREASED IN AUTOIMMUNE HEPATITIS COMPARED TO MASH AND CAN BE TOGGLED BY PPARΑ AGONISTS AND ANTAGONISTS

Read more about HEPATOCYTE DELETION OF REGULATORY T CELLS BY ENCLYSIS IS INCREASED IN AUTOIMMUNE HEPATITIS COMPARED TO MASH AND CAN BE TOGGLED BY PPARΑ AGONISTS AND ANTAGONISTS

<div>Background: The liver is a tolerising organ, to prevent continuous immune activation following the portal influx of antigens from the gut. Regulatory T cells (Treg) dampen inflammation and are important to prevent liver injury. We discovered that hepatocytes engulf and delete live Treg cells by enclysis, which was distinct from known cell-in-cell structure processes and thus can be targeted specifically (PMID: 31693899).

TP53BP2 IS ASSOCIATED WITH HBsAg CLEARANCE IN PEGINTERFERON-ALFA-TREATED CHRONIC HEPATITIS B

Read more about TP53BP2 IS ASSOCIATED WITH HBsAg CLEARANCE IN PEGINTERFERON-ALFA-TREATED CHRONIC HEPATITIS B

<div>Background: Hepatitis B surface Antigen (HBsAg) loss occurs in a minor fraction of patients with Chronic Hepatitis B (CHB) under interferon therapy. Identifying the host factors critical for CHB cure can help recognize those who would benefit from interferon therapy.

A POSITIVE FEEDBACK BETWEEN CHOLESTEROL SYNTHESIS AND THE PENTOSE PHOSPHATE PATHWAY RATHER THAN GLYCOLYSIS PROMOTES HEPATOCELLULAR CARCINOMA

Read more about A POSITIVE FEEDBACK BETWEEN CHOLESTEROL SYNTHESIS AND THE PENTOSE PHOSPHATE PATHWAY RATHER THAN GLYCOLYSIS PROMOTES HEPATOCELLULAR CARCINOMA

<div>Background: Hepatic cholesterol accumulation and hypercholesterolemia are considered as the risk factors of hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol lowering drugs for the treatment of HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated.

HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH A HIF-1α AND TGF-β1 DEPENDENT PATHWAY

Read more about HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH A HIF-1α AND TGF-β1 DEPENDENT PATHWAY

<div>Background:

DYNAMIC EVOLUTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ACROSS TUMOR STAGES AND TREATMENTS

Read more about DYNAMIC EVOLUTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ACROSS TUMOR STAGES AND TREATMENTS

<div>Background: Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer management. We aimed to assess the dynamic evolution of ctDNA in patients with hepatocellular carcinoma (HCC).

A RANDOMIZED CONTROLLED TRIAL COMPARING SUSTAINED LOW EFFICIENCY DIALYSIS WITH CONTINUOUS RENAL REPLACEMENT THERAPY FOR SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY IN CRITICALLY ILL PATIENTS WITH CIRRHOSIS (NCT04494542)

Read more about A RANDOMIZED CONTROLLED TRIAL COMPARING SUSTAINED LOW EFFICIENCY DIALYSIS WITH CONTINUOUS RENAL REPLACEMENT THERAPY FOR SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY IN CRITICALLY ILL PATIENTS WITH CIRRHOSIS (NCT04494542)

<div>Background: Continuous renal replacement therapy (CRRT) is the preferred mode of dialysis in critically ill hemodynamically unstable patients and in addition removes the inflammatory cytokines that accumulate in sepsis. Sustained low-efficiency dialysis (SLED) is a hybrid modality of intermittent dialysis with the advantage of metabolic control, hemodynamic stability, at a reduced cost.

ROLE OF LONG TERM ALBUMIN THERAPY IN TREATMENT OF DECOMPENSATED CIRRHOSIS

Read more about ROLE OF LONG TERM ALBUMIN THERAPY IN TREATMENT OF DECOMPENSATED CIRRHOSIS

<div>Background: Cirrhosis now has the 10th highest mortality rate worldwide. Most cirrhosis deaths are caused by the emergence of clinical decompensation, and 4%–12% of those who have the disease, experience at least one episode of decompensation per year. These patients are highly susceptible to infections due to increased systemic inflammation leading to kidney failure and death.

SIX-YEAR FOLLOW-UP OF MANAGING PREDOMINANTLY HISPANIC PATIENTS WITH SIGNIFICANT STEATOSIS AT A PRIMARY CARE CLINIC

Read more about SIX-YEAR FOLLOW-UP OF MANAGING PREDOMINANTLY HISPANIC PATIENTS WITH SIGNIFICANT STEATOSIS AT A PRIMARY CARE CLINIC

<div>Background:

AN ADVANCED PRACTICE PROVIDER (APP) DRIVEN, WEIGHT INTERVENTION IN LIVER DISEASE (WILD) CLINICAL PATHWAY ACHIEVES MORE MEANING WEIGHT LOSS IN PATIENTS WITH MASLD COMPARED TO STANDARD OR CARE

Read more about AN ADVANCED PRACTICE PROVIDER (APP) DRIVEN, WEIGHT INTERVENTION IN LIVER DISEASE (WILD) CLINICAL PATHWAY ACHIEVES MORE MEANING WEIGHT LOSS IN PATIENTS WITH MASLD COMPARED TO STANDARD OR CARE

<div>Background: As the prevalence of obesity and MASH continues to grow, novel treatment options are needed to prevent progression as there are currently no medications approved to treat MASH. Weight loss has been shown to be an effective treatment with a 5% weight loss reversing steatosis and a 10% weight loss reversing liver fibrosis. Clinical trials using lifestyle-based weight loss interventions in MASH have been shown to achieve >5% total body weight loss (TBWL) in 30% of patients and >10% TBWL in 10% of patients.

Subscribe to